Monoaminoguanidine Uses, Dosage, Side Effects and more
Monoaminoguanidine has been developed by Synvista Therapeutics, Inc for the treatment of diabetic kidney disease. It is an advanced glycation end product inhibitor which manages diabetic nephropathy, either alone or in combination with other therapies. It is beneficial in treating patients with diabetic nephropathy.
| Attribute | Details |
|---|---|
| Trade Name | Monoaminoguanidine |
| Generic | Pimagedine |
| Pimagedine Other Names | Aminate base, Aminoguanidine, Guanyl hydrazine, Hydrazinecarboximidamide, Monoaminoguanidine, Pimagedine |
| Type | |
| Formula | CH6N4 |
| Weight | Average: 74.0851 Monoisotopic: 74.059246212 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
Uses
Investigated for use/treatment in diabetic kidney disease.
How Monoaminoguanidine works
Monoaminoguanidine reportedly inhibits the formation of glycosylated proteins (advanced glycosylation end-products) and has other actions including inhibition of aldose reductase.
